This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VAXART (VXRT) delivered earnings and revenue surprises of -400% and 90.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does VAXART, INC. (VXRT) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
by Sweta Killa
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for VAXART, INC. (VXRT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 15.79% and 1,258%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline
by Zacks Equity Research
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B
by Zacks Equity Research
ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.
Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Brookdale Senior Living (BKD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Brookdale (BKD) delivered earnings and revenue surprises of -10% and 0.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to Buy
by Zacks Equity Research
VAXART, INC. (VXRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VAXART, INC. (VXRT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 6.67% and -9.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: VAXART, INC. (VXRT) Q3 Earnings Expected to Decline
by Zacks Equity Research
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.
Vaxart (VXRT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Vaxart (VXRT) has been struggling lately, but the selling pressure may be coming to an end soon.
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 7.14% and -79.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?